From adjuvant to neo‐adjuvant chemotherapy in high‐risk breast cancer: The experience of the Milan Cancer Institute. Steiner award lecture 1992
From adjuvant to neo‐adjuvant chemotherapy in high‐risk breast cancer: The experience of the Milan Cancer Institute. Steiner award lecture 1992
复制标题
高危乳腺癌从辅助化疗到新辅助化疗：米兰癌症研究所 1992 年斯坦纳奖讲座的经验。
DOI：
--
复制
发表时间：
1993
影响因子：
6.4
通讯作者：
G. Bonadonna
中科院分区：
文献类型：
--
作者：
G. Bonadonna
在本世纪的过去四分之一中，可切除的乳腺癌已经成为无数临床和实验室研究的主题，这些研究旨在开发降低肿瘤死亡率的一般策略或特异性治疗。只有在测试辅助化疗价值的初始现代试验提供的治疗结果之后，这种频繁且复杂的恶性肿瘤才被明确地认为是潜在的全身性疾病（Fisher等人，1975; Bonadonna等人，1976年）。从20世纪70年代初开始，米兰癌症研究所逐步开展了一系列前瞻性对照研究，涉及约3,500名高危患者，以回答特定的生物学和临床问题。关于患者选择、治疗方式和存活结果的细节已经发表（Bonadonna，1992; Zambetti等人，1992; Moliterni等人，1991; Buzzoni等人，1991; Bonadonna等人，1990年）。本报告总结了与我们在淋巴结阳性肿瘤（12个周期，6 vs. 12个周期）和淋巴结阴性肿瘤中使用辅助CMF的初步经验相关的最相关结果。然后更新后续的辅助试验，采用序贯化疗，包括含阿霉素的方案。最近的临床研究，涉及主要（新辅助）化疗和长期医源性发病率也将提到，给出一些细节。
During the past quarter of this century, resectable breast cancer has become the subject of innumerable clinical and laboratory investigations aimed at developing general strategies or specific treatments to reduce tumor mortality. This frequent and complex malignancy was definitely recognized as a potentially systemic disease only after the therapeutic results provided by the initial modern trials testing the value of adjuvant chemotherapy (Fisher et al., 1975; Bonadonna et al., 1976). From the early 1970s, the Milan Cancer Institute has progressively mounted a series of prospective controlled studies involving approximately 3,500 high-risk patients to answer specific biological and clinical questions. Details on patient selection, treatment modalities and survival results have been published (Bonadonna, 1992; Zambetti et al., 1992; Moliterni et al., 1991; Buzzoni et al., 1991; Bonadonna et al., 1990). This report summarizes the most relevant findings relative to our initial experience with adjuvant CMF in node-positive tumors (12 cycles, 6 vs. 12 cycles) and in node-negative tumors. It then updates subsequent adjuvant trials utilizing sequential chemotherapy, including adriamycin-containing regimens. More recent clinical studies involving primary (neo-adjuvant) chemotherapy and long-term iatrogenic morbidity will also be mentioned, giving some details.
影响因子：
11.2
作者：
B. Fisher;N. Gunduz;E. Saffer
通讯作者：
B. Fisher;N. Gunduz;E. Saffer